1
Home
Companies

Brii Biosciences

Brii Biosciences
Leadership team

Dr. Zhi Hong Ph.D. (Co-founder, Exec. Chairman & CEO)

Dr. Ankang Li C.F.A., J.D., Ph.D. (Chief Financial & Strategy Officer, Company Sec. and Exec. Director)

Dr. Eleanor de Groot Ph.D. (Chief Technology Officer)

Products/ Services
Biotechnology, Health Care, Innovation Management, Pharmaceutical
Number of Employees
100 - 500
Headquarters
San Francisco, California, United States
Established
2018
Revenue
5M - 20M
Traded as
HKG:2137
Social Media
URL
https://www.briibio.com
Overview
Location

Summary
History
Mission
Vision
Key Team
Recognition and Award
References
Summary
Brii Biosciences Limited engages in the development of medicines for the treatment of infectious and central nervous system diseases. The company develops BRII-778 and BRII-732, which are in phase I clinical trials for the treatment of HIV patients; BRII-179 and BRII-835, which are in Phase 2 to evaluate the combination of these two HBV mechanisms for Hepatitis B; BRII-179, a recombinant protein-based HBV immunotherapeutic candidate that is in Phase 1b/2a; BRII-835, which has completed Phase-2 for patients with chronic HBV infection; and Amubarvimab/romlusevimab combination therapy for the treatment of COVID-19. It also develops BRII-296 for the treatment of PPD; BRII-297 for treatment of various depressive disorders; BRII-636, BRII-672, and BRII-693 for the treatment of multi-drug resistant/extensive drug resistant (MDR/XDR) gram-negative infections; and BRII-658 for the treatment of MDR/XDR tuberculosis and non-tuberculosis mycobacteria. The company was incorporated in 2017 and is based in Beijing, China.
History

Brii Biosciences was founded in 2015 by the collaboration of the HBM Healthcare Investments and the Fisher Health Group. The company quickly established itself as a leader in developing medicines to address the unmet medical needs of patients in China and around the world.

Mission
To provide innovative therapies that improve the lives of people worldwide
Vision
To be the leading global healthcare company focused on developing and commercializing immunotherapies and biologics
Key Team

Dr. David Margolis M.D., M.P.H. (VP & Head of Infectious Diseases Therapy Area)

Dr. Susannah Cantrell Ph.D. (Chief Bus. Officer)

Ms. Karen Del Barrio Neuendorff (Chief People Officer & Head of HR)

Mr. Coy Stout (Head of Patient Advocacy)

Dr. Li Yan M.D., Ph.D. (Chief Medical Officer)

Dr. Lianhong Xu Ph.D. (Head of Discovery)

Dr. Qing Zhu Ph.D. (Head of China R&D)

Recognition and Awards
2015 – The Fisher Health Group and HBM Healthcare were awarded the “Best Newcomer” award for their joint venture, Brii Biosciences, by Forbes Magazine.
References

https://in.investing.com/equities/brii-biosciences

https://finance.yahoo.com/quote/2137.HK/profile?p=2137.HK

https://www.crunchbase.com/organization/brii-biosciences

https://www.briibio.com

Dive deeper into fresh insights across Business, Industry Leaders and Influencers, Organizations, Education, and Investors for a comprehensive view.

Brii Biosciences
Leadership team

Dr. Zhi Hong Ph.D. (Co-founder, Exec. Chairman & CEO)

Dr. Ankang Li C.F.A., J.D., Ph.D. (Chief Financial & Strategy Officer, Company Sec. and Exec. Director)

Dr. Eleanor de Groot Ph.D. (Chief Technology Officer)

Products/ Services
Biotechnology, Health Care, Innovation Management, Pharmaceutical
Number of Employees
100 - 500
Headquarters
San Francisco, California, United States
Established
2018
Revenue
5M - 20M
Traded as
HKG:2137
Social Media
URL
https://www.briibio.com